Dan Chard'un ücretlendirmesi Medifast'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$29m
Mar 31 2024	n/a	n/a	US$68m
Dec 31 2023	US$7m	US$1m	US$99m
Sep 30 2023	n/a	n/a	US$120m
Jun 30 2023	n/a	n/a	US$133m
Mar 31 2023	n/a	n/a	US$142m
Dec 31 2022	US$6m	US$981k	US$144m
Sep 30 2022	n/a	n/a	US$151m
Jun 30 2022	n/a	n/a	US$157m
Mar 31 2022	n/a	n/a	US$165m
Dec 31 2021	US$7m	US$914k	US$164m
Sep 30 2021	n/a	n/a	US$158m
Jun 30 2021	n/a	n/a	US$150m
Mar 31 2021	n/a	n/a	US$125m
Dec 31 2020	US$6m	US$909k	US$103m
Sep 30 2020	n/a	n/a	US$95m
Jun 30 2020	n/a	n/a	US$76m
Mar 31 2020	n/a	n/a	US$76m
Dec 31 2019	US$5m	US$843k	US$78m
Sep 30 2019	n/a	n/a	US$74m
Jun 30 2019	n/a	n/a	US$72m
Mar 31 2019	n/a	n/a	US$64m
Dec 31 2018	US$2m	US$675k	US$56m
Sep 30 2018	n/a	n/a	US$47m
Jun 30 2018	n/a	n/a	US$40m
Mar 31 2018	n/a	n/a	US$34m
Dec 31 2017	US$2m	US$650k	US$28m

Tazminat ve Piyasa: Dan 'nin toplam tazminatı ($USD 7.04M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).

Tazminat ve Kazançlar: Dan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Dan Chard (59 yo)

8yrs

Görev süresi

US$7,039,062

Tazminat

Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Chard	Executive Chairman & CEO	8yrs	US$7.04m	1.46% $ 3.0m
James Maloney	Chief Financial Officer	4.3yrs	US$2.01m	0.092% $ 187.4k
Anthony Tyree	Chief Business Operations Officer	2.8yrs	US$1.61m	0.12% $ 239.7k
Jason Groves	Executive VP	12.9yrs	US$1.63m	0.12% $ 238.7k
Nicholas Johnson	Chief Field Operations Officer	5.7yrs	US$1.70m	0.095% $ 195.2k
Jonathan MacKenzie	VP of Finance & Chief Accounting Officer	3.1yrs	Veri yok	0.0052% $ 10.7k
Steven Zenker	Vice President of Investor Relations	1.6yrs	Veri yok	Veri yok
Claudia Greninger	Chief Human Resources Officer	5yrs	Veri yok	Veri yok

4.6yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: MED 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Chard	Executive Chairman & CEO	8yrs	US$7.04m	1.46% $ 3.0m
Jeffrey Brown	Lead Independent Director	9.3yrs	US$263.42k	0.15% $ 299.8k
George Bray	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Hoer	Independent Director	6.3yrs	US$249.72k	0.079% $ 161.0k
Andrea Thomas	Independent Director	5.3yrs	US$249.72k	0.059% $ 120.2k
John Foreyt	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ming Xian	Independent Director	6.3yrs	US$219.61k	Veri yok
Lawrence Cheskin	Chairman of Scientific Advisory Board	15.9yrs	Veri yok	Veri yok
Sylvia Rowe	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Scott Schlackman	Independent Director	9.3yrs	US$252.44k	0.073% $ 149.6k
John Hayes	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Mark Messina	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

8.0yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MED 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8 yıldır).

Medifast Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Director recently sold US$109k worth of stock

Independent Director notifies of intention to sell stock

Lead Independent Director notifies of intention to sell stock

Medifast, Inc., Annual General Meeting, Jun 14, 2023

Independent Director notifies of intention to sell stock

Insufficient new directors

Recent updates

Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation

Medifast Business Continues To Shrink, Stock Still Risky

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Medifast, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 15% to US$21.25

Medifast: Significant Undervaluation Even As Struggles Persist

At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

Investor sentiment deteriorates as stock falls 25%

Consensus EPS estimates fall by 54%

The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

First quarter 2024 earnings: EPS misses analyst expectations

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Medifast: Cheap Valuation, Uncertain Future

Independent Director recently sold US$109k worth of stock

Independent Director notifies of intention to sell stock

Medifast Is Getting Attractive

Investor sentiment deteriorates as stock falls 17%

Consensus revenue estimates fall by 15%

New major risk - Revenue and earnings growth

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Full year 2023 earnings: EPS misses analyst expectations

Medifast Provides Earnings Guidance for the First Quarter of 2024

Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Price target decreased by 14% to US$62.50

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Investor sentiment deteriorates as stock falls 16%

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Consensus EPS estimates increase by 11%, revenue downgraded

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Now 21% undervalued after recent price drop

Medifast, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Insider selling

Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Medifast, Inc. Announces Optavia Active Now Available

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023

Lead Independent Director notifies of intention to sell stock

Price target decreased by 14% to US$80.00

Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Price target increased by 31% to US$93.00

Medifast Unveils New Product Line, Optavia Active

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Now 20% undervalued after recent price drop

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023

Medifast: In Survival Mode Against Diet Pills And The Recession

Medifast Holds Value During Headwinds

Medifast, Inc., Annual General Meeting, Jun 14, 2023

Consensus EPS estimates fall by 25%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Director notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Full year 2022 earnings: EPS exceeds analyst expectations

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Medifast, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?